Siddha Treatment for COVID 19- a Pilot Study

Effectiveness Of Siddha Medicine In The Treatment Of COVID 19 Patients- a Pilot study

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2020/07/026632

Enrollment

Registered

2020-07-16

Start date

Unknown

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere

Interventions

Intervention1: 1. AAdathodai kudineer 2. thaalisathi chooranam thulasi chooranam pavala parpam 3. bramanandha bairava mathirai 4. thoothuvalai nei: 1. AAdathodai kudineer-15-30 ml bd with Oral Admin

Eligibility

Inclusion criteria

Inclusion criteria: Patients with the diagnosis of laboratory confirmed COVID 19

Exclusion criteria

Exclusion criteria: 1. Patients With other Acute Respiratory Distress Syndrome or other comorbidities of lungs 2. Pregnant and Lactating Mothers 3. Patients with severe primary respiratory disease or other pathogenic microbial pneumonia that needs to be identified with COVID 19. 4. patients participating in other clinical trials

Design outcomes

Primary

Measure	Time frame
To determine the effectiveness of Siddha Medicine in Acceleration of recovery or Reduction in number of days to become test negative / symptom free in COVID 19 patientsTimepoint: 3 month	—

Secondary

Measure	Time frame
To determine the reduction in risk of disease prognosis and Intensive care support Timepoint: 3 month	—

Countries

India

Contacts

Public ContactDr J Nikil Niva

Government Siddha Medical College

nikilniva@gmail.com7200333774

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Jun 11, 2026